-
公开(公告)号：US09881135B2
公开(公告)日：2018-01-30
申请号：US14651550
申请日：2013-12-13
申请人： Metabogen AB
摘要： The present invention relates to the identification of a person having risk for developing type 2 diabetes (T2D) by determining the presence or absence of specific genes, gene clusters, genera or species of bacteria in the person's gastrointestinal microbiota. More specifically the invention relates to a model to identify an individual having or at risk of developing type 2 diabetes (T2D) using metagenomic clusters (MGCs), wherein said model is characterized by using different metagenomic clusters for different population groups. Also provided is the use of such a model in the identification of a person having risk for developing type 2 diabetes (T2D).
-
公开(公告)号：US20180179584A1
公开(公告)日：2018-06-28
申请号：US15904845
申请日：2018-02-26
申请人： METABOGEN AB
IPC分类号： C12Q1/689 , A61K31/00 , A61K31/015 , A61K35/747 , G01N33/49 , C12Q1/6883 , G01N30/00 , G16H50/30 , G06F19/22 , A61K35/00
CPC分类号： C12Q1/689 , A61K31/00 , A61K31/015 , A61K35/747 , A61K2035/115 , C12Q1/6883 , C12Q2600/112 , C12Q2600/16 , G01N30/00 , G01N33/49 , G01N2407/00 , G01N2800/323 , G01N2800/50 , G16B30/00 , G16H50/30
摘要： The present invention provides the use of metagenomics to identify a compositional or functional alteration of the gut metagenome related to atherosclerosis or atherosclerotic associated disease. Also provided are methods to identify a person having risk for atherosclerosis and associated diseases by determining the presence of specific bacterial groups or species and also metabolic functions in the person's gut microbiota and to use such information to develop a prevention or treatment strategy.
-
公开(公告)号：US20150317444A1
公开(公告)日：2015-11-05
申请号：US14651550
申请日：2013-12-13
申请人： METABOGEN AB
IPC分类号： G06F19/00
摘要： The present invention relates to the identification of a person having risk for developing type 2 diabetes (T2D) by determining the presence or absence of specific genes, gene clusters, genera or species of bacteria in the person's gastrointestinal microbiota. More specifically the invention relates to a model to identify an individual having or at risk of developing type 2 diabetes (T2D) using metagenomic clusters (MGCs), wherein said model is characterised by using different metagenomic clusters for different population groups. Also provided is the use of such a model in the identification of a person having risk for developing type 2 diabetes (T2D).
摘要翻译： 本发明涉及通过确定该人胃肠道微生物群中特定基因，基因簇，细菌或种类的细菌的存在或不存在来鉴定患有2型糖尿病（T2D）的风险的人。 更具体地，本发明涉及使用宏基因组（MGC）鉴定具有或具有发展型2型糖尿病（T2D）风险的个体的模型，其中所述模型的特征在于对不同群体群使用不同的宏基因组。 还提供了这种模型在鉴定患有发生2型糖尿病（T2D）风险的人中的用途。
-
4.发明申请Identification of a Person having Risk for Atherosclerosis and Associated Disease by the Person's Gut Microbiome and the Prevention of such Diseases 审中-公开确定人肠道微生物组织和动脉粥样硬化及相关疾病风险的人群及预防这类疾病公开(公告)号：US20150299776A1
公开(公告)日：2015-10-22
申请号：US14433535
申请日：2013-10-03
申请人： Metabogen AB
IPC分类号： C12Q1/68 , G01N33/49 , G06F19/00 , A61K35/747 , G01N30/00 , G06F19/22 , A61K31/015
CPC分类号： C12Q1/689 , A61K31/00 , A61K31/015 , A61K35/747 , A61K2035/115 , C12Q1/6883 , C12Q2600/112 , C12Q2600/16 , G01N30/00 , G01N33/49 , G01N2407/00 , G01N2800/323 , G01N2800/50 , G16B30/00 , G16H50/30
摘要： The present invention provides the use of metagenomics to identify a compositional or functional alteration of the gut metagenome related to atherosclerosis or atherosclerotic associated disease. Also provided are methods to identify a person having risk for atherosclerosis and associated diseases by determining the presence of specific bacterial groups or species and also metabolic functions in the person's gut microbiota and to use such information to develop a prevention or treatment strategy.
摘要翻译： 本发明提供了宏基因组学技术用于鉴定与动脉粥样硬化或动脉粥样硬化相关疾病相关的肠道巨变细胞的组成或功能改变。 还提供了通过确定特定细菌群体或物种的存在以及人的肠道微生物群中的代谢功能以及使用这些信息来开发预防或治疗策略来鉴定具有动脉粥样硬化和相关疾病风险的人的方法。
-
-
-
搜索结果
4 条记录 (耗时 0.011 秒)